TSR-011-isomer
| Code | Size | Price |
|---|
| TAR-T29020-5mg | 5mg | £1,091.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T29020-50mg | 50mg | £2,143.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T29020-100mg | 100mg | £2,801.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
TSR011-isomer, a TrKA/ALK inhibitor, is used potentially for the treatment of solid tumours and lymphoma.
CAS:
1388225-79-3
Formula:
C33H43F2N5O3
Molecular Weight:
595.736
Purity:
0.98
SMILES:
CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c2cc(CN3CCC(CC3)C(C)(C)O)ccc2[nH]c1=N/C(=O)c1cc(F)cc(F)c1
References
1. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017 Feb 4. pii: S0163-7258(17)30020-7. doi: 10.1016/j.pharmthera.2017.02.006. [Epub ahead of print] Review. PubMed PMID: 28174090.
2. Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep-Oct;21(5):378-82. doi: 10.1097/PPO.0000000000000142. Review. PubMed PMID: 26389762; PubMed Central PMCID: PMC5242382.
3. Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47. doi: 10.1177/1758834015617355. Review. PubMed PMID: 26753004; PubMed Central PMCID: PMC4699265.
4. Pall G. The next-generation ALK inhibitors. Curr Opin Oncol. 2015 Mar;27(2):118-24. doi: 10.1097/CCO.0000000000000165. Review. PubMed PMID: 25588040.